Assessment of Regulatory requirements and filing procedure of Drug Master File for Brazil, Europe and South Africa

  • Riya Patel Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (CHARUSAT), CHARUSAT Campus, Changa- 388 421, Anand, Gujarat, India.
  • Kunal R. Girase Zydus API Park, Zydus Lifesciences Ltd. Vadodara. Vadodara, Gujarat.
  • Venkateshwara T. Rao Zydus API Park, Zydus Lifesciences Ltd. Vadodara. Vadodara, Gujarat.
  • Amit A. Patel Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (CHARUSAT), CHARUSAT Campus, Changa- 388 421, Anand, Gujarat, India.
  • Ravish J. Patel Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (CHARUSAT), CHARUSAT Campus, Changa- 388 421, Anand, Gujarat, India.
DOI https://doi.org/10.22270/ijdra.v10i2.517

Abstract

A Drug Master File is a record that consists of detailed, correct data approximately an Active Pharmaceutical Ingredient (API) or Dosage Form of a Finished Product (FP). It is a classified document containing thorough, accurate, and up-to-date information regarding the active medicinal ingredient and medicament. A DMF is divided into two sections: (a) Open part (the Applicant's Part), which includes all of the details needed to determine the quality of a product. And (b) the Closed Part (Restricted Part). The Restricted Part (Closed Part) comprises openly undisclosed manufacturing method knowledge only given to authorized individuals. This compilation aims to offer a comparison of DMF regulatory necessities in addition to the exact data for the registration of lively pharmaceutical ingredients (API) for common drugs in various regulatory governments, including EUROPE (EDQM, EMA), BRAZIL (ANVISA), and SOUTH AFRICA (SAHPRA). This review will provide information on the differences and similarities in the DMF filing requirements in EUROPE, BRAZIL, and SOUTH AFRICA. The regulatory criteria for API registration vary by jurisdiction. Despite the existence and widespread adoption of an ICH-CTD standard format, there are also some limitations. There are a few particular requirements set provided to drug authorities along with the submission. The registration procedure is a regulatory undertaking that permits a person/organization/sponsor/innovator to get permission to participate in the regulation process for fetching marketing authorization/approval.

Keywords: Drug Master File (DMF), Regulatory Requirement, Brazil (ANVISA), Europe (EMA, EDQM), South Africa (SAHPRA)

Downloads

Download data is not yet available.

References

1. Drug Master Files Guidance for Industry [Internet]. FDA;2019 [cited 3 Jan,2022]. Available from:
https://www.fda.gov/media/131861/download
2. Introduction to Brazil [Internet]. anvisa [cited 2022 Jan 03]. Available from:
https://www.gov.br/anvisa/pt-br
3. RESOLUTION OF THE COLLEGIATE BOARD - RDC No. 359/2020 [Internet]. coifa.anvisa.gov.br; 2020[cited 3 Jan, 2022]. Available from:
https://coifa.anvisa.gov.br/rdc/359.html
4. Guidance for electronic submissions for Certificates of Suitability (CEP) applications [Internet]. EUROPE; 2018 [cited 2022 Jan 03]. Available from:
https://www.edqm.eu/sites/default/files/guidance_for_esubmissions_for_cep_applications-january2018.pdf
5. Guideline on Active Substance Master File Procedure [Internet] ema.europa.eu; 2019 [cited 2022 Jan 03] Available from:
https://www.ema.europa.eu/en/documents/report/final-guideline-active-substance-master-file-procedure-revision-4_en.pdf
6. Guideline for the API Master file (APIMF) procedure[Internet]. sahpra.org; 2021[cited 2022 Jan 03]. Available from:
https://www.sahpra.org.za/wp-content/uploads/2020/01/bfa8f4702.59_GuidelinefortheAPIMFProcedure_Oct19_v1.pdf
7. Guideline on summary of regulatory requirement for active substances in the quality part of the dossier [Internet]. ema.europa; 2005 [cited 2021 Oct. 26]. Available from:
https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-summary-requirements-active-substances-quality-part-dossier-revision-1_en.pdf
8. Vaseem AM, Nagarjuna D, Ramaiah M, Nagabhushanam M, Venkateswarlu B. Regulatory requirements of drug master files by food and drug administration (USA), european medicines agency (Europe) and health canada (Canada) and their comparison. Journal of Global Trends in Pharmaceutical Sciences. 2014;5(4):2220-2224.
9. Tripathi C, Girme A, Champaneri S, Patel RJ, Hingorani L. Nutraceutical regulations: An opportunity in ASEAN countries. Nutrition International Journal of Drug Regulatory Affairs [Internet]. 2020 Jun 1 [cited 2022 Jan 03]; 74: 110729. Available from:
https://www.researchgate.net/publication/357862213_Current_Regulatory_requirements_for_registration_of_nutraceuticals_in_ASEAN
10. Patel R, Patel A, Gohil T. Regulatory requirement for the approval of generic drug in Cambodia as per ASEAN common technical dossier (ACTD). International Journal of Drug Regulatory Affairs [Internet]. 2018 [cited 2022 Jan 03];6(2):67-71. Available from:
https://www.researchgate.net/publication/326298579_Regulatory_requirement_for_the_approval_of_Generic_Drug_in_Cambodia_as_per_ASEAN_Common_Technical_Dossier_ACTD
11. Agrawal M, Alexander A, Khan J, Giri TK, Siddique S, Dubey SK, Patel RJ, Gupta U, Saraf S, Saraf S. Recent biomedical applications on stem cell therapy: a brief overview. Current Stem Cell Research & Therapy. Europe PMC [Internet]. Europepmc; 2019 Feb 01[cited 2022 Jan 05];14(2):127-36. Available from:
https://europepmc.org/article/MED/17485394
Statistics
216 Views | 566 Downloads
How to Cite
Patel, R., K. R. Girase, V. T. Rao, A. A. Patel, and R. J. Patel. “Assessment of Regulatory Requirements and Filing Procedure of Drug Master File for Brazil, Europe and South Africa”. International Journal of Drug Regulatory Affairs, Vol. 10, no. 2, June 2022, pp. 14-27, doi:10.22270/ijdra.v10i2.517.
Issue
Vol 10 No 2 (2022): VOLUME 10, ISSUE 2, 2022
Section
Review
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.

I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.

Download link for COPYRIGHT FORM